Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU
Part of paid clinical trials in Gainesville, Florida.
- Sponsor
- BioMarin Pharmaceutical
- Study ID
- NCT03694353
- Phase
- PHASE3
- Status
- Completed
Conditions
- Phenylketonuria (PKU)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Pegvaliase — DRUG40-60mg/day
Study Details
This is a Phase 3 open-label extension study enrolling adult patients with PKU who were previously treated with pegvaliase in Studies PAL-003 (NCT00924703) or 165-302 (NCT02468570). The study is designed to evaluate the long-term safety and efficacy of pegvaliase administered at doses \> 40 mg/day to 60 mg/day.
Key Dates
- Start date
- Sep 13, 2018
- Status verified
- Feb 2022
- Primary completion
- Jan 13, 2021
- Completion
- Jan 13, 2021
Study Design
- Enrollment
- 37 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: PegvaliaseBeginning on Day 1, subjects will receive the same dose and regimen of pegvaliase they were receiving in 165-302 or PAL-003 (pegvaliase dosing should continue without interruption from the previous study). Subsequent revisions to dosing regimens are allowed following consultation with the medical monitor.
Primary Outcome Measure
Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0 [ Time Frame: Up to Day 741 (approximately Week 106) ]
Locations (17)
Find similar trials in Gainesville, FL
By research site
University of Florida· Gainesville, FLUniversity of South Florida· Tampa, FLAnn & Robert H. Lurie Children's Hospital of Chicago· Chicago, ILIndiana CTSI Clinical Research Center· Indianapolis, INUniversity of Kentucky Medical Center· Lexington, KYWayne State University, Center for Molecular Medicine and Genetics, Pediatrics and Pathology· Detroit, MI
Related Studies
- A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)Recruiting · BioMarin Pharmaceutical · Aurora, Colorado
- A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)Recruiting · BioMarin Pharmaceutical · Aurora, Colorado
- A Long-Term Study of JNT-517 in Participants With PhenylketonuriaPHASE3 · Recruiting · Otsuka Pharmaceutical Development & Commercialization, Inc. · Gainesville, Florida